<DOC>
	<DOCNO>NCT00923962</DOCNO>
	<brief_summary>GLP-1 incretin hormone discharge intestine food intake . The hormone know powerful insulinotropic trophic effect beta cell pancreas currently use anti-diabetic agent patient type 2 diabetes ( T2DM ) . GLP-1 receptor widely distribute include endothelial cell coronary skeletal muscle circulation myocardium . GLP-1-receptor study knock-out mouse show exhibit reduce myocardial contractility reduce diastolic heart function . GLP-1 also show beneficial cardiovascular effect patient acute myocardial infarction dog dilate cardiomyopathy left ventricle function endothelial dysfunction improve GLP-1 treatment via insulin-independent mechanism . Preclinical study indicate exogenous administrate GLP-1 physiological concentration improve perfusion never test human . It also unknown whether GLP-1 directly increase glucose/metabolite uptake across cardiac skeletal muscle insulin independent manner . Unpublished study however indicate improvement cardiovascular system largely dependent upon high blood glucose level partially dependent upon antiglycemic effect GLP-1 . In proposed study investigator wish examine physiological role GLP-1 receptor stimulation regard perfusion , metabolic improvement well cardiac inotropic . These study conduct healthy T2DM patient .</brief_summary>
	<brief_title>Endothelial Metabolic Effects Glucagon-like Peptide-1 ( GLP-1 ) Coronary Circulation Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Caucasians 18 Emitted nonacute coronary arteriography ( CAG ) Gentofte hospital BMI 2335 kg/m2 Normal hemoglobin Who give informed consent Those type 2 diabetes : HbA1c 610 % Those without type 2 diabetes : Normal oral glucose tolerance test ( OGTT ) accord WHO criteria Liver disease ( ALAT &gt; 2x normal ) Diabetic nefropati ( Creatinine &gt; 130 ÂµM albuminuria ) Treatment medicine pause 12 hour intervention Pregnancy breastfeed Insulin glitazone treatment Healthy control : close family history diabetes Unstable angina pectoris NonSTEMI Atrial fibrillation Valvular disease LVEF &lt; 50 % Severe systemic disease Type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Basic science</keyword>
	<keyword>Type 2 Diabetes mellitus</keyword>
	<keyword>Glucagon like peptid-1</keyword>
	<keyword>Coronary Bloodflow</keyword>
	<keyword>Metabolite uptake</keyword>
</DOC>